InvestorsHub Logo
Post# of 253158
Next 10
Followers 840
Posts 120463
Boards Moderated 18
Alias Born 09/05/2002

Re: ciotera post# 212042

Sunday, 06/25/2017 7:34:44 PM

Sunday, June 25, 2017 7:34:44 PM

Post# of 253158
Re: 2022 forecasts for HCV drugs

EvaluatePharma’s report (#msg-132374740) has ABBV/ENTA’s Maviret (G/P) outselling GILD’s Vosevi (SOF/VEL/VOX) in 2022 by 10%, FWIW. (See table on page 34 of full report.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.